AK112 is an investigational humanized IgG1 VEGF × PD-1 bsAb. A phase I clinical trial (NCT04047290) evaluated the efficacy of AK112 in the treatment of patients with solid tumors.

2024年4月19日 · Ivonescimab is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously. Here, we report the first-in-human, phase 1a …

In this trial, we aimed to assess the efficacy and safety of ivonescimab combined with chemotherapy for first line advanced or metastatic NSCLC in patients (pts) with squamous …

2024年3月12日 · Bispecific antibodies (BsAbs) enhance tumor killing by guiding various effector cells to tumor cells in a non-MHC-restricted manner. BsAbs facilitate the interaction between T …

2024年4月24日 · Ivonescimab (AK112) is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously. This is the first-in-human phase 1a …

China's Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) for its bispecific antibody (BsAb) AK112, targeting programmed death …

2024年7月27日 · AK112, a bsAb targeting PD-1 and VEGF, has shown promising antitumor activity and safety in its Phase II trial [109]. This efficacy extends to first-line treatment in …

AK112: AK112 is a bsAb targeting both PD-1 × VEGF and has been developed by Akeso. AK112 was first evaluated in a phase-I study in advanced solid tumors resistant/refractory to standard …

2024年4月16日 · A clinical trial by Zhou et al. investigated the use of AK112 (a VEGF/PD-1 BSAB; dosage, > 10 mg/kg) in patients with advanced NSCLC. Their findings revealed an …

2023年8月4日，中山大学肿瘤防治中心张力教授牵头开展的 PD-1 / VEGF 双抗 （AK112, 依沃西）联合化疗治疗晚期非小细胞肺癌（NSCLC）的Ⅱ期临床研究结果在国际顶级医学期刊《柳 …